Join the Menopausal Disorders group to help and get support from people like you.
Menopausal Disorders News (Page 6)
Related terms: Change of Life, Menopause, Climacteric
Long-Term Study of Postmenopausal Women Does Not Support Many Preventive Therapies
THURSDAY, May 2, 2024 – The longitudinal Women's Health Initiative trials do not support hormone therapy for cardiovascular disease prevention, calcium and vitamin D supplementation for universal...
Hormonal Meds for Birth Control, Menopause Linked to Brain Tumors
THURSDAY, March 28, 2024 – The contraceptive injection Depo-Provera and two drugs used for menopause relief could be linked to a heightened risk for brain tumors in some women, a new study warns....
FDA Approves Veozah (fezolinetant) for the Treatment of Vasomotor Symptoms Due to Menopause
TOKYO, May 13 2023 – Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Veozah (fezolinetant) 45 mg once daily for the treatment of moderate to severe v...
FDA Approves Bijuva (estradiol and progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause
BOCA RATON, Fla.--(BUSINESS WIRE)--Oct. 29, 2018-- TherapeuticsMD, Inc, an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has a...
TherapeuticsMD Announces FDA Approval of Imvexxy (estradiol vaginal inserts) for the Treatment of Dyspareunia Due to Menopause
BOCA RATON, Fla., May 30, 2018 /PRNewswire/ – TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the United States Food and Drug Administration (FDA)...
FDA Approves Intrarosa (prasterone) for Postmenopausal Women Experiencing Dyspareunia
November 17, 2016 – The U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of...
FDA Approves Brisdelle - First Non-Hormonal Treatment for Hot Flashes Associated with Menopause
June 28, 2013 --The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which...
FDA Approves 10 mcg Dose of Vagifem for the Treatment of Atrophic Vaginitis Due to Menopause
PRINCETON, N.J., Dec. 2 /PRNewswire-FirstCall/ – Novo Nordisk said today that the U.S. Food and Drug Administration (FDA) has approved a 10 mcg dose formulation of Vagifem (estradiol vaginal...
FDA Medwatch Alert: Compounded Menopause Hormone Therapy Drugs
[Posted 01/10/2008] FDA informed healthcare professionals and patients that the Agency sent letters warning seven pharmacy operations that the claims they make about the safety and effectiveness of...
Further information
Related condition support groups
Postmenopausal Symptoms, Hot Flashes